Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Free Cash Flow (2016 - 2026)

Corvus Pharmaceuticals' Free Cash Flow history spans 12 years, with the latest figure at -$10.5 million for Q1 2026.

  • Quarterly Free Cash Flow fell 26.1% to -$10.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$35.1 million through Mar 2026, down 23.0% year-over-year, with the annual reading at -$33.0 million for FY2025, 29.68% down from the prior year.
  • Free Cash Flow came in at -$10.5 million for Q1 2026, down from -$9.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$5.2 million in Q1 2024 to a low of -$10.5 million in Q1 2026.
  • The 5-year median for Free Cash Flow is -$6.4 million (2022), against an average of -$7.1 million.
  • Year-over-year, Free Cash Flow surged 51.59% in 2022 and then crashed 63.83% in 2024.
  • Corvus Pharmaceuticals' Free Cash Flow stood at -$7.5 million in 2022, then skyrocketed by 31.54% to -$5.2 million in 2023, then crashed by 63.83% to -$8.5 million in 2024, then decreased by 8.87% to -$9.2 million in 2025, then decreased by 13.55% to -$10.5 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Free Cash Flow are -$10.5 million (Q1 2026), -$9.2 million (Q4 2025), and -$9.6 million (Q3 2025).